Interventional technology developer AngioDynamics has signed an agreement to acquire RadiaDyne, a private medical diagnostic and device company that develops patient radiation dose monitoring technology.
The deal will broaden AngioDynamics' oncology business, adding RadiaDyne's OARtrac radiation dose monitoring platform to its portfolio, the company said. RadiaDyne also makes IsoLoc/ImmobiLoc, endorectal tools that reduce prostate motion and radiation toxicity, and Alatus, a vaginal balloon packing system that improves dosimetry, according to AngioDynamics.
RadiaDyne's 12-month revenues exceeded $6 million. The acquisition is expected to close by the end of September, AngioDynamics said.
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
